Form 4: Kiniksa Pharmaceuticals Executive Trades Shares

Mark Ragosa, Chief Financial Officer of Kiniksa Pharmaceuticals, reported transactions involving Class A Ordinary Shares, including the acquisition of shares and options.

Summary

• Mark Ragosa, Chief Financial Officer of Kiniksa Pharmaceuticals International, plc, reported several transactions on April 1, 2026.
• These transactions include the acquisition of 5,187 Class A Ordinary Shares and the disposal of 2,510 Class A Ordinary Shares at a price of $48.13 per share.
• Following these transactions, Ragosa beneficially owns 14,763 Class A Ordinary Shares directly.
• Additionally, Ragosa acquired a stock option for 31,150 Class A Ordinary Shares with an exercise price of $48.13, exercisable from April 1, 2026, until March 31, 2036.
• He also acquired 7,800 Restricted Share Units (RSUs) that vest over a four-year period starting April 1, 2026.
• Further acquisitions include 15,600 Performance Share Units (PSUs) which may convert into up to 200% of one Class A Ordinary Share per unit by January 30, 2029.
• Additional RSUs were acquired with varying vesting schedules: 1,750 RSUs granted April 1, 2023, 1,591 RSUs granted April 1, 2024, and 1,846 RSUs granted April 1, 2025, all vesting over four years.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine executive stock transactions and compensation awards rather than significant financial performance or strategic shifts.

Positives

• Acquisition of 5,187 Class A Ordinary Shares by the CFO.
• Acquisition of stock options and various share units (RSUs, PSUs) indicates continued incentive alignment with shareholders.
• The CFO's direct beneficial ownership of 14,763 shares demonstrates a personal stake in the company's performance.

Negatives

• Disposal of 2,510 Class A Ordinary Shares by the CFO at $48.13 per share.

Future Outlook

The vesting schedules for RSUs and PSUs indicate a long-term incentive structure tied to company performance and continued employment.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for executive stock transactions. The details of option grants and RSU/PSU vesting are typical components of executive compensation packages in the pharmaceutical industry, designed to align management interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The disposal of shares by the CFO could be interpreted neutrally as part of personal financial management, but any significant selling by insiders can sometimes be viewed with caution. The acquisition of options and equity awards suggests continued commitment and alignment with shareholder interests.
• Employees: The structure of RSUs and PSUs can serve as a retention tool for key employees, including management.
• Management: The transactions reflect the ongoing compensation and incentive structure for the Chief Financial Officer.

Next Steps

• Vesting of stock options, RSUs, and PSUs according to their respective schedules.
• Potential future transactions by Mark Ragosa based on vesting events and personal financial planning.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Options, Restricted Stock Units, Performance Share Units, Kiniksa Pharmaceuticals, KNSA, Beneficial Ownership, Class A Ordinary Share, Executive Compensation